<DOC>
	<DOCNO>NCT00929266</DOCNO>
	<brief_summary>To study vivo life span healthy volunteer red blood cell generate vitro autologous peripheral stem cell . The study carry 4 phase : - production vitro equivalent 1 ml blood , i.e . 5x10e9 enucleate RBC mononuclear cell isolate HSC graft obtain healthy volunteer donor . - label cRBC 51 Cr - reinjection autologous cRBC - follow receiver maximum 33 day measure half-life span inject cell .</brief_summary>
	<brief_title>Cultured Red Blood Cells : Life Span Vivo Study</brief_title>
	<detailed_description>1 . GENERALITIES 1.1 Clinical grade production cRBC In study cRBC active principle final product subject radioactive chromium labeling . The quantity 5x109 cRBC reinjected determined necessity quantity radioactivity lie 2500 5000 kBq order sufficient sensitivity measure life span . 1.2 Hypothesis test Since cRBC vitro functional characteristic native RBC , hypothesize viable vivo . This viability evaluate measure life span . It compare report life span native RBC , i.e . 30+3 day . 2 . OBJECTIVES OF THE STUDY 2.1 Principal objective Study life span vivo culture Red Blood Cells . 2.2 Evaluation criterion 2.2.1 Principal : The principal criterion measure life span cRBC . It compare report life span native RBC , i.e . 30+3 day . The study involve label cohort cRBC : administration , cohort cRBC age circulate blood disappear end `` life span '' . The result interpret follow manner : - radioactivity first 3 blood sample remain constant ( correction decay ) , take evidence favor absence premature cell destruction . The follow 3 sample draw later [ within limit 30 day , measurement radioactivity sample longer possible due decay chromium 51 , elimination chromium cell rate 1.2 % per day lack precision radioactive count low activity ] . One conclude life span cRBC superior 33 day . - , first 3 sample , radioactivity diminishes significant manner earlier reference curve , three sample take close together enable estimation mean life span cRBC . 3 . EXPERIMENTAL PLAN 3.1 Type study Clinical feasibility assay . 3.2 Experimental plan The study carry 4 phase : 1. production vitro equivalent 1mL blood , i.e . 5x109 enucleated RBC , mononuclear cell isolate HSC graft obtain healthy benevolent donor , 2. label cRBC 51Cr , accord classical protocol use study life span red blood cell , 3. reinjection autologous cRBC donor , 4. follow-up receiver maximal duration 33 day measure half-life injected cell . 4 . CHARACTERISTICS OF THE RECEIVERS 4.1 Description study population The choice conduct study healthy volunteer patient base necessity healthy physiological context avoid situation could lead hemolysis . As protocol require mobilization growth factor , donor peripheral stem cell ( PSC ) receive G-CSF . The voluntary receiver recruit among intra-familial donor PSC , order avoid unnecessary exposure healthy donor G-CSF . In context mobilization HSC , receive 5 day subcutaneous injection G-CSF dose 10 µg/kg body weight . 4.1.1 Collection mononuclear cell cytapheresis Characteristics start material : Peripheral blood hematopoietic stem cell take production culture RBC unless graft destine patient contains &gt; 7x106 CD34+ cells/kg body weight patient receiver , cell dose establish literature sufficient reconstitute hematopoiesis patient receive allogenic graft . Thus research protocol incur loss chance patient . 4.1.2 Isolation CD34+ cell protocol The CD34+ cell use research select positive immunomagnetic selection column use Isolex® system . A minimum 45x106 CD34+ cell necessary good functioning system . These limit factor oblige u use start material stem cell mobilize G-CSF . After removal sample study , graft contain minimum 7x106 CD34+ cells/kg body weight patient . The post-selection start material consist clinical grade CD34+ cell purify immunomagnetic selection . A purity 50 % CD34+ cell obtain immunomagnetic selection . The percentage viable cell determine stain trypan blue . The purified CD34+ cell frozen 4 % albumin solution contain 10 % DMSO condition 2.5 mL cryotubes contain 1x106 CD34+ cell . After thaw , cell viability 50 % . A minimum 1 million viable CD34+ cell necessary seeding culture day 0 . 4.1.3 Biological characterization cRBC The active principle filter cRBC final product cRBC label 51Cr . As product reinjected immediately label , characterization perform active principle involve follow element : The active principle consist : 1 . RBC characterize : - morphology ( slide stain May-Grunwald-Giemsa ) , - hemoglobin content ( MHC &gt; 25 pg measure Sysmex XE-2100 automate ) ( see 3.2.S.4.3 ) ; 2. acidophilic erythroblast &lt; 1.2 % ( &gt; 10,000 cell count slide ) ; 3. exclusion cell type &gt; 10,000 cell count slide . 4.1.4 Sufficient criterion active principle ( cRBC ) The product label chromium present follow characteristic : - 5 10x109 RBC MHC &gt; 25 pg , - &lt; 1.2 % acidophilic erythroblast , - absence leukocyte . The remain microbiological control know posteriori . 4.1.5 Labeling chromium 51 This step perform nuclear medicine clinic . Labeling carry : - use suspension cRBC , - sterile solution [ 51Cr ] sodium chromate activity 37 MBq/mL calibration . The labeling procedure perform clinically sterile condition . The suspension inject 0.3 mL fraction ( constraint link measurement 51Cr activity syrinx injection ) use 2 mL syrinx close stopper . The maximal volume reinjected 5 mL intravenous route . 4.1.6 Sufficient criterion final product label 51Cr The labeled product inject healthy volunteer present follow characteristic : - 51Cr activity 2,500 KBq ( minimum ) 5,000 KBq ( maximum ) , - absence 51Cr bound cell . 4.1.7 Injection receiver This step take place within 2 month stem cell collection . Direct intravenous injection label cRBC volume 1 mL , room reserve administration radioactive drug , situate nuclear medicine clinic adjacent preparation laboratory , regulatory reason . Maintenance venous route end period surveillance . Collection 2 sample 10 mL blood EDTA venous puncture bend elbow , T+1h T+3h injection . Criteria discharge clinic : absence fever shivering , normal blood pressure normal clinical examination . Total duration post-injection surveillance : 4 hour . 4.2 Planning appointment measurement life span cRBC Collection 10 mL sample venous puncture bend elbow follow-up receiver carry CIC St Antoine . Transfer tubes nuclear medicine clinic . - The third sample take T+24h injection . - The follow 3 take day choose accord decay estimate first sample ( T+48h T+30 day injection ) . The lack establishment fix date sample justified necessity adapt kinetics homogenous population cRBC , present unknown . A clinical examination carry appointment . After perform measurement , sample destroy . In conclusion , approach several advantage : 1 . It avoid inject growth factor , G-CSF , healthy volunteer sole objective study . 2 . The autologous situation avoids immunological risk risk transmission infectious agent . 3 . 51Cr emitter gamma radiation energy 320 keV radioactive period 27.7 day . The irradiation result study involve measurable risk . No particular radioprotective precaution need envisage , either receiver contact .</detailed_description>
	<criteria>1 . Aptitude donation PSC validate accord selection criterion intrafamilial donor hematopoietic stem cell ( HSC ) : Age &gt; 18 year &lt; 65 year ; Search interview risk factor pertain transmissible disease ; Absence significant medical antecedent ; Absence severe evolutive pathology ( renal , hepatic cardiac insufficiency ) ; Serological status follow antibody ( Ab ) antigens ( Ag ) determine 30 day precede donation PSC : antiHIV 1+2 Ab ( 2 technique ) P24 antigenemia antiHCV Ab HBs Ag antiHBc Ab antiHBs Ab antiHTLV I+II Ab syphilis antiCMV Ab antitoxoplasmosis Ab antiEBV Ab Determination blood group search irregular agglutinin ( SIA ) . 2 . Presence addition follow clinical biological characteristic require assay healthy volunteer : Results follow biological test within normal limit clinically acceptable : hemogram , hepatic function , renal function ; Absence hemoglobinopathy hemoglobin electrophoresis profile ; Absence G6PD PK deficiency ; Absence radiological examination context research protocol within last 12 month ; Normal arterial pressure control 5 min rest recline position : &lt; 140 / 90 three measurement 2 min interval ; ECG 12 derivation particularity ; Signature specific statement inform consent participate study life span cRBC , addition donation HSC . Women childbearing age ; Donors carry marker infection : antiHIV 1+2 Ab ( 2 technique ) , P24 antigenemia , antiHCV Ab , HBs Ag , antiHTLV I+II Ab , syphilis ; Hemoglobinopathy ; G6PD PK deficiency ; Acute chronic systemic disease ; Antecedents hypersensitivity drug ; Signs , symptoms result biological test lie outside limit clinically acceptable healthy subject ; Known allergy chromium .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>peripheral stem cell ( PSC ) donor</keyword>
	<keyword>culture red blood cell</keyword>
	<keyword>In vivo half life</keyword>
</DOC>